Scilex Holding Co
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
SCLX$1.61-7.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss including noncontrolling interest | $(327,948) | $(66,347) |
| Adjustments to reconcile net loss to net cash proceeds from operating activities: | ||
| Depreciation and amortization | 3,036 | 3,042 |
| Amortization of debt issuance costs and debt discount | — | 94 |
| Non-cash operating lease cost | 542 | 547 |
| Loss on debt extinguishment, net | 1,103 | — |
| Stock-based compensation | 9,849 | 10,884 |
| Loss (gain) on derivative liability | 60,323 | (2,367) |
| Financing costs and allocated expense for financial instruments at fair value | 7,148 | 2,526 |
| In-process research and development expense | 5,426 | — |
| Transaction costs expensed related to Semnur Business Combination | 140,000 | — |
| Change in fair value of debt and liability instruments | 36,511 | 11,961 |
| Change in fair value of equity investments | (8,282) | — |
| Change in fair value of digital assets | (4,702) | — |
| Allowances for expected credit losses | — | 1,186 |
| Other | 175 | 392 |
| Changes in operating assets and liabilities: | ||
| Accounts receivables, net | 14,501 | 1,831 |
| Inventory | 1,290 | 1,496 |
| Prepaid expenses and other | 6,823 | (2,857) |
| Other long-term assets | — | (30) |
| Accounts payable | 11,353 | 2,266 |
| Accrued payroll | (1,110) | (1,706) |
| Accrued expenses | 14,894 | 2,463 |
| Accrued rebates and fees | 50,864 | 52,051 |
| Operating lease liability | (523) | (593) |
| Other long-term liabilities | 14 | (24) |
| Net cash proceeds from operating activities | 21,287 | 16,815 |
| Investing activities | ||
| Acquisition consideration paid in cash for Romeg intangible asset acquisition | (450) | (450) |
| Purchase of equity securities | — | (2,000) |
| Cash paid for in-process research and development, net | (200) | — |
| Purchase of convertible promissory note from Denali | (50) | (30) |
| Net cash used for investing activities | (700) | (2,480) |
| Financing activities | ||
| Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement | — | 156 |
| Proceeds from issuance of Revolving Facility | — | 93,389 |
| Proceeds from issuance of FSF Deposit | — | 10,000 |
| Repayment of Revolving Facility | — | (96,189) |
| Repayment of Oramed Note | — | (36,700) |
| Repayment of Convertible Debentures | — | (4,375) |
| Repayment of Tranche B Notes principal and interest | (15,967) | — |
| Cash consideration paid in connection with the repurchase of Penny Warrants | (13,000) | (300) |
| Payments on purchased revenue liability | (2,373) | — |
| Transaction costs paid in connection with share repurchase | (996) | — |
| Proceeds from issuance of shares under direct offerings | — | 25,000 |
| Payments of direct offering issuance costs | — | (2,844) |
| Payments of debt issuance costs | (71) | — |
| Excise tax paid in connection with share repurchase | (860) | — |
| Proceeds from Semnur Business Combination | 33 | — |
| Transaction costs paid related to Semnur Business Combination | — | — |
| Proceeds from exercise of December 2024 RDO Warrants | 10,237 | — |
| Proceeds from stock options and warrant exercised and ESPP | 17 | 915 |
| Payments in lieu of fractional shares for Reverse Stock Split | (1) | — |
| Net cash used for financing activities | (22,981) | (10,948) |
| Net change in cash, cash equivalents and restricted cash | (2,394) | 3,387 |
| Cash, cash equivalents and restricted cash at beginning of period | 3,272 | 4,729 |
| Cash, cash equivalents and restricted cash at end of period | $878 | $8,116 |
| Non-cash investing and financing activities | ||
| Issuance costs related to February 2024 BDO, April 2024 RDO and December 2024 RDO included in accrued expenses and accounts payables | $— | $1,430 |
| Net liabilities assumed in Semnur Business Combination | $12,822 | $— |
| Derecognition of Scilex's investment in Denali in connection with Semnur Business Combination | $2,470 | $— |
| Exercise of December 2024 RDO Warrants in exchange for settlement of Tranche B Notes principal and interest | $2,689 | $— |
| Purchase of equity investment in Datavault AI Inc in exchange for Bitcoin | $8,069 | $— |
| Bitcoin acquired in exchange for shares of Semnur | $200,000 | $— |
| Additions to intangible assets included in accrued expenses | $1,000 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.